Xiao Zhang - Clin Res & Dev, Jiangsu Hengrui Med Co Ltd

基本信息

浏览量：17

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 12 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Toripalimab Plus Bevacizumab Versus Sorafenib As First-Line Treatment for Advanced Hepatocellular Carcinoma (HEPATORCH): a Randomised, Open-Label, Phase 3 Trial

Yinghong Shi,Guohong Han,Jian Zhou,Xuetao Shi,Weidong Jia,Ying Cheng, Yongdong Jin, Xiangdong Hua,Tianfu Wen,Jianbing Wu,Shanzhi Gu,Yuxian Bai,Xiangcai Wang,Tao Zhang,Zhiyu Chen,Bixiang Zhang, Ming Huang,Hongming Liu,Yilei Mao,Ledu Zhou, Rui Wang,Yunfeng Shan,Wu Zhang,Tianqiang Song,Yabing Guo,Fuxiang Zhou,Bingfeng Shao,Mingjun Zhang, Bo Liang,Jinfang Zheng, Guoping Zhang,Jie Shen,Weiwen Su, Feng Zhang,Yifu He,Sheng Hu,Rong Liu,Chengwu Zhang,Shunli Shen,Hui Zeng, Tsang-En Wang,Wenzhi Guo,Yan Shen,Yajin Chen,Yong Li, J Samol,Hongtao Hu, Wenhua Zhang,Chengyou Du,Enxiao Li,Chao Liu,Choo Su Pin,Xun Li,Hao Xu, Jee-Fu Huang,Chunyi Hao,Jing Lv, Wei Wang, Qian Xu, Aobing Bai,Xiao Zhang, Bifeng Liu, Chunlei Jin,Jia Fan

The lancet Gastroenterology & hepatologyno. 7 (2025): 658-670

引用0浏览0WOS引用

Sorafenib Extends the Lifespan of C. Elegans Through Mitochondrial Uncoupling Mechanism

Lu-Yao Zheng, Yan-Xin Da, Xiu Luo,Xiao Zhang,Zhi-Jie Sun,De -Li Dong

Free Radical Biology and Medicine (2024): 101-113

引用1浏览0WOS引用

Metabolic Dysregulation and Emerging Therapeutical Targets for Hepatocellular Carcinoma

Danyu Du,Chan Liu,Mengyao Qin,Xiao Zhang,Tao Xi,Shengtao Yuan,Haiping Hao,Jing Xiong

Acta Pharmaceutica Sinica B（2022）

引用270浏览0WOS引用

270

A Phase 1 Study of Dalpiciclib, a Cyclin-Dependent Kinase 4/6 Inhibitor in Chinese Patients with Advanced Breast Cancer

Zhang Pin,Xu Binghe,Gui Lin,Wang Wenna,Xiu Meng,Zhang Xiao,Sun Guilan,Zhu Xiaoyu,Zou Jianjun

Biomarker Research（2021）

引用22浏览0WOS引用

Camrelizumab Plus Oxaliplatin-Based Chemotherapy As First-Line Therapy for Advanced Biliary Tract Cancer: A Multicenter, Phase 2 Trial

Xinni Chen,Shukui Qin,Shanzhi Gu,Zhenggang Ren,Zhendong Chen,Jianping Xiong,Ying Liu,Zhiqiang Meng,Xiao Zhang,Linna Wang,Xiaojing Zhang,Jianjun Zou

International Journal of Cancer（2021）

引用35浏览0WOS引用

Camrelizumab Plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Yuan-Yuan Qu,Hai-Liang Zhang,Hongqian Guo,Hong Luo,Qing Zou,Nianzeng Xing,Shujie Xia,Zhongquan Sun,Xuepei Zhang,Chaohong He,Jinling Cai,Xiao Zhang,Quanren Wang,Ding-Wei Ye

CLINICAL CANCER RESEARCH（2021）

引用22浏览0WOS引用

Camrelizumab Plus Famitinib for Advanced Renal Cell Carcinoma or Unresectable Urothelial Carcinoma: Updated Results from a Phase II Trial

Yuan-Yuan Qu,Qing Zou,Hongqian Guo,Nianzeng Xing,Zhongquan Sun,Weiqing Han,Hong Luo,Shujie Xia,Xuepei Zhang,Chaohong He,Hailiang Zhang,Jinling Cai,Xiao Zhang,Quanren Wang,Dingwei Ye

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用2浏览0引用

A Phase I Study of SHR6390, a Cyclin-Dependent Kinase 4/6 Inhibitor in Patients with Advanced Breast Cancer (ABC)

Pin Zhang,Binghe Xu,Lin Gui,Wenna Wang,Meng Xiu,Xiao Zhang,Guilan Sun,Xiaoyu Zhu,Jianjun Zou

Journal of Clinical Oncology（2020）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn